

Taiwanese firm UBI-Asia inks COVID-19 vaccine deal with Paraguay

22 June 2021 | News

The Vaxxinity UB-612 vaccine is the first Multitope protein/synthetic peptide vaccine to fight the SARS-CoV-2 virus

Vaxxinity, a US-based company pioneering the development of a new class of immunotherapeutic vaccines, in close collaboration with Taiwanese firm UBI-Asia, has announced a purchase order for its COVID-19 vaccine, UB-612, with the Government of Paraguay, contingent upon issuance of an Emergency Use Authorization (EUA) by the Taiwanese Food and Drug Administration (TFDA), which will trigger an EUA in Paraguay.

The UB-612 vaccine is expected to be delivered later this summer, pending issuance of an EUA by the TFDA and subsequent registration by Paraguay's National Health Surveillance Authority (DINAVISA). As the Ministry of Health and Welfare noted the leadership shown on June 16 by the Government of Paraguay guarantees that Paraguay will be one of the first countries in the world to receive UB-612 once it is issued an EUA.

Vaxxinity, in close collaboration with its partner, UBI-Asia, is completing a large Phase 2 clinical trial of UB-612 in Taiwan, with support from Taiwan's Ministry of Health and Welfare, and will soon begin its Phase 2/3 efficacy trial in India in partnership with Aurobindo. Vaxxinity has also announced a global logistics partnership with Maersk, the world's largest shipping and integrated logistics provider, that creates a framework for all transportation and supply chain services that will be needed to deliver UB-612 around the world.

The Vaxxinity UB-612 vaccine is the first Multitope protein/synthetic peptide vaccine to fight the SARS-CoV-2 virus. The UB-612 vaccine elicits broad humoral or cellular immune responses against several viral proteins to protect against COVID-19.